DDInter508 DDInter1652
Desogestrel, a prodrug, is a third generation progestogen and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activity. Desogestrel is now produced semi-synthetically from naturally occurred plant steroids. In the US, desogestrel is found only in combination with [ethinyl estradiol]. The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Desogestrel {u} (Compound) resembles {v} (Compound) Ethinylestradiol
Desogestrel {u} (Compound) resembles {v} (Compound) Norgestimate
Desogestrel {u} (Compound) binds {v} (Gene) PGR
Desogestrel {u} (Compound) palliates {v} (Disease) polycystic ovary syndrome
Desogestrel {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Desogestrel {u} (Compound) causes {v} (Side Effect) Rash
Desogestrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rosuvastatin
Desogestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Albiglutide
Desogestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Desogestrel {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Desogestrel (Compound) resembles Ethinylestradiol (Compound)
Desogestrel (Compound) resembles Norgestimate (Compound)
Desogestrel (Compound) binds PGR (Gene)
Desogestrel (Compound) palliates polycystic ovary syndrome (Disease)
Desogestrel (Compound) is included by Progesterone Congeners (Pharmacologic Class)
Desogestrel (Compound) causes Rash (Side Effect)
Desogestrel may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin
Desogestrel may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Desogestrel may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone
Desogestrel may lead to a major life threatening interaction when taken with Bexarotene